EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Emerging therapies for MASLD and their impact on plasma lipids

Madison Nguyen, Amon Asgharpour, Dave L Dixon, Arun J Sanyal, Anurag Mehta

American Journal of Preventive Cardiology · 2024-03 · 17 · 100638

DOI: 10.1016/j.ajpc.2024.100638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2024-03. Verfasst von Madison Nguyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, United States. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-dysfunction associated steatotic liver disease (MASLD) affects 1 out of every 3 individuals in the adult population and the disease prevalence is predicted to increase worldwide. Patients with MASLD are also burdened by cardiovascular disease, which is the leading cause of mortality in this population. Complex metabolic derangements such as insulin resistance and atherogenic dyslipidemia affect patients with MASLD. In patients with MASLD, treatment such as pharmacotherapy may be best directed towards improving the adverse concomitant metabolic disorders associated with MASLD, particularly the ones that may contribute to MASLD. Herein, we discuss conventional therapies that target cardiometabolic risk factors which have the potential to improve hepatic injury, and summarize emerging therapies that target hepatic receptors, fibrosis, and fatty acid oxidation in patients with MASLD. Given the relationship between hepatic injury which leads to MASLD, insulin resistance, and ultimately atherogenic dyslipidemia our review uniquely delves into the effects of conventional and emerging therapies for MASLD on plasma lipid parameters.

Schlagwörter

Stichwörter der Autor:innen

AtherosclerosisCardiometabolic diseaseDyslipidemiaMetabolic-dysfunction associated steatohepatitisMetabolic-dysfunction associated steatotic liver disease

Autor:innen und Institutionen

  • Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, United States.
  • VCU Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, Richmond, VA, United States.
  • Department of Pharmacotherapy and Outcome Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, United States.
  • VCU Health Pauley Heart Center, Richmond, VA, United States.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Nguyen, M., Asgharpour, A., Dixon, D. L., Sanyal, A. J., & Mehta, A. (2024). Emerging therapies for MASLD and their impact on plasma lipids. American Journal of Preventive Cardiology, 17, 100638. https://doi.org/10.1016/j.ajpc.2024.100638

Vancouver

Nguyen M, Asgharpour A, Dixon DL, Sanyal AJ, Mehta A. Emerging therapies for MASLD and their impact on plasma lipids. American Journal of Preventive Cardiology. 2024;17:100638. doi:10.1016/j.ajpc.2024.100638

BibTeX
@article{Nguyen2024,
  author = {Nguyen, Madison and Asgharpour, Amon and Dixon, Dave L and Sanyal, Arun J and Mehta, Anurag},
  title = {Emerging therapies for MASLD and their impact on plasma lipids},
  journal = {American Journal of Preventive Cardiology},
  year = {2024},
  volume = {17},
  pages = {100638},
  doi = {10.1016/j.ajpc.2024.100638}
}
Kostenlos starten →